The adaptation of enkephalin, tachykinin and monoamine neurons of the basal ganglia following neonatal dopaminergic denervation is dependent on the extent of dopamine depletion.
This study examined whether dopamine (DA) is necessary for the normal development of striatal enkephalin and striatonigral tachykinin peptide systems. The neurotoxin, 6-hydroxydopamine (6-OHDA) was used to induce DA deficiency on the third day of the postnatal period in Sprague-Dawley rat pups. The animals were sacrificed at 60 days of age. The levels of Met5-enkephalin (ME) and substance P (SP) were determined by radioimmunoassay and preproenkephalin (PPE) and preprotachykinin (PPT) mRNA abundance in the striatum were assessed by hybridization analysis. The concentrations of DA, 5-hydroxytryptamine (5-HT) and their acid metabolites were determined by high-pressure liquid chromatography with electrochemical detection. The lesioned animals were grouped on the basis of the degree of loss of DA, and changes in ME, SP and 5-HT systems were correlated with respect to the degree of DA loss. The nature and extent of the changes in these systems were dependent on the degree of DA depletion. A loss of more than 90% DA was necessary to result in increased levels of ME and its PPE mRNA and reduced levels of SP and its PPT mRNAs; however, increased levels of 5-HT could be observed at a lower degree of DA loss. The results indicate that the normal development of enkephalin and tachykinin and 5-HT systems of basal ganglia are dependent on the availability of DA and/or the integrity of the nigrostriatal dopaminergic neurons. The results are relevant to our further understanding of the neurobiology of DA deficiency disorders.
Sivam
S P
SP
Department of Pharmacology and Toxicology, Indiana University School of Medicine, Gary 46408.
Krause
J E
JE
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000222:Adaptation, Physiological / Q000502:physiology*; D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D001479:Basal Ganglia / Q000187:drug effects / Q000502:physiology*; D015306:Biogenic Monoamines / Q000502:physiology; D002851:Chromatography, High Pressure Liquid; D003714:Denervation; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D004744:Enkephalin, Methionine / Q000235:genetics / Q000502:physiology; D005260:Female; D006892:Hydroxydopamines; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008297:Male; D009474:Neurons / Q000502:physiology*; D009693:Nucleic Acid Hybridization; D016627:Oxidopamine; D012333:RNA, Messenger / Q000378:metabolism; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000378:metabolism; D013373:Substance P / Q000235:genetics / Q000502:physiology
D015306:Biogenic Monoamines; D006892:Hydroxydopamines; D012333:RNA, Messenger; D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; D013373:Substance P; D006897:Hydroxyindoleacetic Acid; D004744:Enkephalin, Methionine; D016627:Oxidopamine; D004298:Dopamine